These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 1904164

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Once versus twice daily administration of didanosine in children with symptomatic HIV-associated disease who were intolerant to or clinically deteriorated on zidovudine. The Italian Pediatric Collaborative Study Group on Didanosine.
    Marchisio P, Principi N, Gabiano C, Galli L, Gattinara GC, Caselli D, Zuccotti G, La Regina A, Paga C.
    Antivir Ther; 1997 Jan; 2(1):47-55. PubMed ID: 11322266
    [Abstract] [Full Text] [Related]

  • 3. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
    Bozzette SA, Kanouse DE, Duan N, Berry S, Richman DD.
    Antivir Ther; 1996 Jan; 1(1):21-32. PubMed ID: 11322256
    [Abstract] [Full Text] [Related]

  • 4. Zidovudine (Retrovir) update.
    Rachlis AR.
    CMAJ; 1990 Dec 01; 143(11):1177-85. PubMed ID: 2224694
    [Abstract] [Full Text] [Related]

  • 5. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL.
    APMIS Suppl; 2003 Dec 01; (114):1-37. PubMed ID: 14626050
    [Abstract] [Full Text] [Related]

  • 6. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1999 Feb 01; 469():1-361. PubMed ID: 12579204
    [Abstract] [Full Text] [Related]

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Feb 01; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb 01; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Report on a 3-year follow-up zidovudine (AZT) treatment in a group of HIV-positive patients with congenital clotting disorders.
    Sartori MT, Mares M, Zerbinati P, Stocco D, Girolami A.
    Haematologia (Budap); 1994 Feb 01; 26(1):17-27. PubMed ID: 7959371
    [Abstract] [Full Text] [Related]

  • 15. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov 01; 78(11):717-22. PubMed ID: 14672050
    [Abstract] [Full Text] [Related]

  • 16. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.
    Clin Ther; 1999 Nov 01; 21(11):1853-63. PubMed ID: 10890257
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.